The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acq - P2P | Acquired

About Oxford Glycosciences

was a technology developer in the fields of glycobiology and proteomics. Utilizing its technology, the company developed a lead pharmaceutical product Zavesca, that was approved by the European Commission, and established proteomics collaborations with several multi-national pharmaceutical companies.

Oxford Glycosciences Headquarter Location

1950 Lake Park Drive

Smyrna, Georgia, 30080,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Oxford Glycosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxford Glycosciences is included in 1 Expert Collection, including Omics.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Oxford Glycosciences Patents

Oxford Glycosciences has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Vaccines, G protein coupled receptors, Vaccination, Transcription factors, Cell signaling


Application Date


Grant Date



Related Topics

Vaccines, G protein coupled receptors, Vaccination, Transcription factors, Cell signaling



Latest Oxford Glycosciences News

Celltech Group PLC (“CELLTECH”) Cash Offer for Oxford Glycosciences PLC (“OGS”)

Jan 30, 2015

Source NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA OR JAPAN Celltech Group  Plc ("Celltech") Cash Offer For Oxford Glycosciences Plc ("OGS") April 11, 2003 -- Celltech is pleased to note the announcement earlier today that the Board of OGS now recommends that OGS Shareholders accept Celltech’s all cash offer of 182 pence per share. Celltech also announces that it has today purchased a further 20,525,985 OGS Shares at a price of 182 pence per share, representing approximately 36.65 per cent. of the issued share capital of OGS. As announced on 24 March 2003, Celltech has previously purchased 5,892,971 OGS Shares representing approximately 10.52 per cent of the issued share capital of OGS and, as at 3.00pm (London time) today, valid acceptances of its Offer had been received in respect of 1,421,210 OGS Shares (including those represented by OGS ADSs), representing approximately 2.54 per cent. of the issued share capital of OGS. Accordingly, and subject to settlement of today's purchases, an aggregate of 27,840,166 OGS Shares (including those represented by OGS ADSs), representing approximately 49.71 per cent. of the issued share capital of OGS, have been acquired by Celltech or validly assented to its Offer. As a result of today's purchases, Celltech's Offer of 182 pence in cash for each OGS Share is now conditional only on Celltech having received acceptances in respect of OGS Shares which, together with OGS Shares acquired or agreed to be acquired, will result in Celltech (and any person acting in concert with Celltech) holding OGS Shares carrying more than 50 per cent. of the voting rights in OGS. Save as set out above, neither Celltech, nor any person acting or deemed to be acting in concert with Celltech, owned any OGS Shares on 22 January 2003 (being the business day prior to the commencement of the offer period), nor have any of such persons acquired or agreed to acquire any OGS Shares (including OGS Shares represented by OGS ADSs) during the offer period and no acceptances of the Offer have been received from any persons acting or deemed to be acting in concert with Celltech. Shareholders in OGS who wish to accept the Offer, and who have not yet done so, should return their Form(s) of Acceptance as soon as possible. Further Forms of Acceptance can be obtained from Lloyds TSB Registrars, The Causeway, Worthing, West Sussex BN99 6DA or by telephoning the Helpline on 0870 600 0673 (if calling from the United Kingdom), (1) 800 858 1202 (if calling from the United States or if you are an OGS ADS Holder) or +44 (0) 1903 702 767 (if calling from elsewhere). If you are an OGS ADS Holder and wish to accept the Offer, you should follow the instructions set out in the Letter of Transmittal. If OGS Shareholders or OGS ADS Holders are in any doubt as to the procedures for acceptance, they should contact the Helpline on the above numbers. A further announcement will be made in due course. Source: Evaluate™

  • Where is Oxford Glycosciences's headquarters?

    Oxford Glycosciences's headquarters is located at 1950 Lake Park Drive, Smyrna.

  • What is Oxford Glycosciences's latest funding round?

    Oxford Glycosciences's latest funding round is Acq - P2P.

  • Who are the investors of Oxford Glycosciences?

    Investors of Oxford Glycosciences include Celltech, SR One, Edelson Technology Partners and Thomas McNerney & Partners.

  • Who are Oxford Glycosciences's competitors?

    Competitors of Oxford Glycosciences include BioDelivery Sciences International, WaferGen Bio-systems, Allozyne, Crossject Medical Technology, Entelos and 11 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


IEP develops biocatalytic (enzymatic) processes for the manufacture of high-value chemicals or pharmaceutical intermediates that reduce cost, time, amounts of toxic solvents used and unwanted side products when compared to traditional chemistry. The company currently has 13 industrial processes in commercial operation and offers routes of synthesis to more than 50 products.

Cogentus Pharmaceuticals

Cogentus Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006. Cogentus is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Flamma Logo

Flamma specializes in the manufacture of active ingredients and intermediates for the pharmaceutical, nutraceutical and cosmetic industries.


QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.


KIYATEC specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to current standard of care drugs prior to treatment selection.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.